This month, Dr. Claudio Dagostin spent a few hours with us at Intelligent Pharma. Dr. Dagostin is an expert from the University of Cambridge in protein-protein interactions and gave us an interesting talk about the role of this type of interaction in nature and in therapeutics. Definitively, working on disrupting protein-protein interactions is a challenge and “tricks” and methods that were useful when working, for instance in enzyme inhibitors, are not necessarily useful in this new field of research.
17/03/2014 | Tags:
There is a widespread consensus that the use of a rigid model of a protein target is highly limiting as does not take into account natural conformational variations of the protein and, in particular, the thermodynamics and kinetics of the binding process of a drug, which can be of a great importance in drug discovery. The computational methodology that allows taking into account protein conformational variations is Molecular Dynamics (MD). However, until few months ago, to run MD experiments was extremely costly as High Performance Computing (HPC) was needed, for instance, big cluster of computers.
21/01/2014 | Tags:
Intelligent Pharma has historically focused all its activities on drug discovery. Our clients range from big pharmaceutical companies to small and virtual biotech, most of them focused on “red life sciences” or, in other words, focused on developing new drugs and treatments for human health.
However, since some years ago, we also detected molecular modeling opportunities in other fields beyond drug discovery, such as, cosmetics, nutrition, petrochemistry or even research on new materials. Hence, we opened our focus, tools and expertise to such new fields. If your business is amongst any of such fields and you are wondering how molecular modeling can add value to your business, please, read the following lines:
26/11/2013 | Tags:
1 of 10